ERBB2 and breast cancer: Interestingly, HER-2 and HER-3, which in this study were found upregulated during tamoxifen treatment, have been identified as a functional unit in experimental breast cancer models, where they cooperate to deregulate the G1 to S transition during cell cycle and thus stimulate mitosis [36].